A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the safest dose and identify any bad side effects of
EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic
cancer who have already received first-line standard chemotherapy.